ARS Pharmaceuticals, Inc.
SPRY
$5.23
-$0.16-2.97%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -215.43M | -197.98M | -171.30M | -80.04M | -48.02M |
| Total Depreciation and Amortization | 1.62M | 1.48M | 1.37M | 979.00K | 609.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.18M | 22.51M | 19.16M | 17.00M | 13.98M |
| Change in Net Operating Assets | -12.77M | -1.08M | -20.10M | -23.31M | -19.37M |
| Cash from Operations | -196.41M | -175.07M | -170.87M | -85.38M | -52.80M |
| Capital Expenditure | -197.00K | -248.00K | -339.00K | -641.00K | -584.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.69M | 55.74M | 57.11M | -68.47M | -6.72M |
| Cash from Investing | 48.50M | 55.50M | 56.77M | -69.11M | -7.31M |
| Total Debt Issued | 96.26M | 96.26M | 96.26M | 97.75M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.11M | 5.02M | 5.68M | 5.43M | 5.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5.17M | 2.76M | 2.66M | 71.20M | 69.38M |
| Cash from Financing | 104.53M | 104.03M | 104.60M | 174.38M | 75.02M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.38M | -15.54M | -9.50M | 19.90M | 14.91M |